**AB**

A review of candida infections [HERE](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1797637/).

A review on this in its entirety is [HERE](https://www.dropbox.com/s/o6z2l65nvq1bzce/-%20Diagnosis%20and%20Treatment%20of%20Fungal%20Infections%20%282015%2C%20Springer%20International%20Publishing%29.pdf?dl=0).

Changing epidemics of candida infections

Kojic Darouiche 2004

[HERE](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC387407/).

Changing epidemiology of candidemia in Australia, JAC 2017.

[HERE](https://www.ncbi.nlm.nih.gov/pubmed/28204502)

Lockhart 2016 Project of

*C aurius* mapping.

54 subjects from India, Pakistan, South Africa and Venezeula.

[HERE](https://www.ncbi.nlm.nih.gov/pubmed/27988485).

**C**

A collection of reviews done on biofilms and candida.

They form biofilms on catheter, pacemakers as well as endogenous materials.

Here are some of the reviews;

Candida and biofilm: [HERE](https://academic.oup.com/femspd/article/74/4/ftw018/2389141).

Another review on biofilm: [HERE](https://www.ncbi.nlm.nih.gov/pubmed/26849383).

HERE too,

Interestingly, *C auris* is not able to form biofilm as good as other candida species and [HERE](https://www.ncbi.nlm.nih.gov/pubmed/28223375) is the proof.

**D**

Meropenem increases the vori level [HERE](https://www.researchgate.net/publication/322862221_Inhibition_of_Voriconazole_Metabolism_by_Meropenem_A_Role_for_Inflammation).

Flucloxacillin reduces voriconazole level [HERE](https://aac.asm.org/content/61/9/e00915-17).

**E**

PK for anidulafungin

It may need to be given a higher LD in critically ill patients.

[HERE](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5278699/).

PK for mica

Not enough in critically ill patients.

[HERE](https://www.ncbi.nlm.nih.gov/pubmed/25963988).

PK for caspo.

Not enough too in critically ill patients.

[HERE](https://www.ncbi.nlm.nih.gov/pubmed/27855112).

**FGH**

TDM guidelines from he British Society for Medical Mycology [HERE](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3977608/).

Antifungal Drug Therapeutic Monitoring: What are the Issues? [HERE](https://link.springer.com/article/10.1007/s40588-015-0019-x).

A targeted review on vori and posaconazole TDM HERE against IA. [HERE](https://www.dropbox.com/s/c29chf00jl7nr4s/Therapeutic%20drug%20monitoring%20for%20IA%20concerning%20VORI%20and%20POSA.pdf?dl=0)

ECMO review and its effect on antifungal drugs as well as antibiotics [HERE](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5535730/).

**I**

Inflammation is associated with higher vori trough concentration.

[HERE](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4249508/).

And [HERE](https://www.researchgate.net/profile/Tjip_Van_Der_Werf/publication/265692506_Inflammation_Is_Associated_with_Voriconazole_Trough_Concentrations/links/56f1193c08aee94ad4de7675/Inflammation-Is-Associated-with-Voriconazole-Trough-Concentrations.pdf?origin=publication_detail) too.